Daiichi Sankyo-Merck’s Patritumab Deruxtecan Achieves Key Goal in Late-Stage Lung Cancer Trial
Daiichi Sankyo and Merck have announced that their investigational drug, patritumab deruxtecan, successfully met its primary endpoint in a late-stage clinical trial. This study demonstrated […]